These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37405660)

  • 21. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.
    Lin J; Lee SL; Russell AM; Huang RF; Batt MA; Chang SS; Ferrante A; Verdino P
    PLoS One; 2021; 16(7):e0254944. PubMed ID: 34297759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and humanization of single-domain antibodies.
    Rossotti MA; Bélanger K; Henry KA; Tanha J
    FEBS J; 2022 Jul; 289(14):4304-4327. PubMed ID: 33751827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanization of Camelid Single-Domain Antibodies.
    Sulea T
    Methods Mol Biol; 2022; 2446():299-312. PubMed ID: 35157279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular immunology approach to antibody humanization and functional optimization.
    Lazar GA; Desjarlais JR; Jacinto J; Karki S; Hammond PW
    Mol Immunol; 2007 Mar; 44(8):1986-98. PubMed ID: 17079018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
    Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
    MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the Developability of an Antigen Binding Fragment by Aspartate Substitutions.
    Sakhnini LI; Greisen PJ; Wiberg C; Bozoky Z; Lund S; Wolf Perez AM; Karkov HS; Huus K; Hansen JJ; Bülow L; Lorenzen N; Dainiak MB; Pedersen AK
    Biochemistry; 2019 Jun; 58(24):2750-2759. PubMed ID: 31117388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single domain camel antibodies: current status.
    Muyldermans S
    J Biotechnol; 2001 Jun; 74(4):277-302. PubMed ID: 11526908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process.
    Xu A; Kim HS; Estee S; ViaJar S; Galush WJ; Gill A; Hötzel I; Lazar GA; McDonald P; Andersen N; Spiess C
    Mol Pharm; 2018 Oct; 15(10):4529-4537. PubMed ID: 30118239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing developability early in the discovery process for novel biologics.
    Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
    MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-survivin single-domain antibodies derived from an artificial library including three synthetic random regions by in vitro selection using cDNA display.
    Suzuki T; Mochizuki Y; Kimura S; Akazawa-Ogawa Y; Hagihara Y; Nemoto N
    Biochem Biophys Res Commun; 2018 Sep; 503(3):2054-2060. PubMed ID: 30119893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating protein-excipient interactions of a multivalent V
    Panchal J; Falk BT; Antochshuk V; McCoy MA
    MAbs; 2022; 14(1):2124902. PubMed ID: 36166705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
    Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
    Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain.
    Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR
    MAbs; 2020; 12(1):1787121. PubMed ID: 32658605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VH-VL orientation prediction for antibody humanization candidate selection: A case study.
    Bujotzek A; Lipsmeier F; Harris SF; Benz J; Kuglstatter A; Georges G
    MAbs; 2016; 8(2):288-305. PubMed ID: 26637054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Classification of CDR-H3 in Single-Domain V
    Kuroda D; Tsumoto K
    Methods Mol Biol; 2023; 2552():61-79. PubMed ID: 36346585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Progress in single-domain antibody derived from heavy-chain antibody].
    Cui HQ; Wang QM
    Sheng Wu Gong Cheng Xue Bao; 2005 May; 21(3):497-501. PubMed ID: 16108383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
    Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
    Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
    MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosting antibody developability through rational sequence optimization.
    Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
    MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RESP2: An uncertainty aware multi-target multi-property optimization AI pipeline for antibody discovery.
    Parkinson J; Hard R; Ko YS; Wang W
    bioRxiv; 2024 Jul; ():. PubMed ID: 39131296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.